In particular, APR’s business model is currently focused on 2 (two) pillars: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements.

APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development.
APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.

The company has started up a direct sales and marketing organizations in selected countries in rare disease products area.

The products developed or under development at APR range from Rx to OTC pharmaceutical products and also include medical devices and nutritional supplements for targeted disease areas.
Examples of marketed products include Cambia (www.cambiarx.com), Zuplenz (www.zuplenz.com), Nexodyn® AOS and PKU Golike.

The company’s R&D efforts are currently focused on the development of improved treatments for rare inherited metabolic disorders, ocular diseases and rare dermatological diseases.